Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004.
We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia. Using operational clinical and cost data, we calculated that the cost of treating leishmaniasis patients with standard pentavalent antimony was US$345 (95% CI 277-488) per patient treated and cured. The cost per DALY averted per patient cured with antimony was estimated to be approximately US$15 000 (95% CI 12 226-21 532).
Vega
Juan Carlos
JC
Universidad Militar Nueva Granada, Santafé de Bogotá, Colombia, and Universidad del Bosque, Bogotá, Colombia.
Sanchez
Boris Fernando
BF
Montero
Luz Mery
LM
Montaña
Rafael
R
Del Pilar Mahecha
Mercedes
M
Dueñes
Bladimir
B
Baron
Angela Rocío
AR
Reithinger
Richard
R
D000981:Antiprotozoal Agents / Q000191:economics* / Q000627:therapeutic use; D003105:Colombia / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D004196:Disease Outbreaks / Q000191:economics*; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology; D008536:Meglumine / Q000191:economics* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000191:economics* / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate